Results 281 to 290 of about 1,512,902 (358)
Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon +4 more
wiley +1 more source
Interplay between RNA‐protein interactions and RNA structures in gene regulation
Methodological advances in mapping transcriptome‐wide RNA‐protein interactions and RNA structures have started to uncover the potential of RNP conformations in gene regulation. Competing RNA–RNA, RNA‐protein and protein–protein interactions shape the compaction and function of RNPs throughout their lifetime and may provide novel therapeutic targets in ...
Jenni Rapakko +2 more
wiley +1 more source
SARS-CoV-2 ORF10 hijacking ubiquitination machinery reveals potential unique drug targeting sites. [PDF]
Zhu K +10 more
europepmc +1 more source
Representation of the suggested mode of action of lactoferrin (Lf) in nonsmall cell lung cancer (NSCLC) A549 cells. Lf induces activation of caspase‐3 by activating p53 and AChE leading to decreased ACh concentrations. In turn, ACh signaling leads to activation of VEGF and AKT and blocking of caspase‐3.
Stuti Goel +9 more
wiley +1 more source
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee +3 more
wiley +1 more source
Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types. [PDF]
Panettieri R +3 more
europepmc +1 more source
DRUG TARGET IDENTIFICATION BY USING ARTIFICIAL INTELLIGENCE
Dr. Y. Anil Kumar*1, B. Kalyani2, D. Arshiya3, S. K. Sony Begum4, T. Komali5, Karan Dhungana6, Laishram Jaichandra Singh7
openalex +1 more source

